CSL Behring, Seattle Children's to develop gene therapies

By The Science Advisory Board staff writers

June 2, 2020 -- CSL Behring, a biotechnology company, and Seattle Children's Research Institute announced that the organizations have entered a strategic alliance to develop stem cell gene therapies for primary immunodeficiency diseases.

The alliance will initially focus on the development of treatments for patients with either Wiskott-Aldrich syndrome or X-linked agammaglobulinemia, rare life-threatening diseases. CSL and Seattle Children's will apply novel gene therapy technology to accelerate research toward clinical trials. Together, the organizations will investigate applying proprietary platform technology, Select+ and Cytegrity, to several preclinical gene therapy programs. Broadly, the research will be associated with commercialization of stem cell therapies, including consistent manufacturing, efficacy, and tolerability.

Copyright © 2020 scienceboard.net

CPhI North America
August 10-12
Philadelphia, Pennsylvania United States
Bioprocessing Summit
August 16-19
Boston, Massachusetts United States
6th Annual CAR-TCR Summit
August 30 - September 2
European Congress of Immunology (ECI) 2021
September 1-4
Belgrade Serbia
Medical Affairs Strategic Summit (MASS)
September 13-15
New Brunswick, New Jersey United States
Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter